Creative Planning Has $418,000 Stock Holdings in AxoGen, Inc. (NASDAQ:AXGN)

Creative Planning grew its position in AxoGen, Inc. (NASDAQ:AXGN) by 152.2% during the third quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 29,790 shares of the medical equipment provider’s stock after purchasing an additional 17,980 shares during the quarter. Creative Planning owned approximately 0.07% of AxoGen worth $418,000 as of its most recent SEC filing.

A number of other institutional investors also recently modified their holdings of AXGN. BNP Paribas Financial Markets raised its position in shares of AxoGen by 8.6% in the first quarter. BNP Paribas Financial Markets now owns 20,820 shares of the medical equipment provider’s stock valued at $168,000 after purchasing an additional 1,651 shares during the period. Roubaix Capital LLC bought a new position in shares of AxoGen in the first quarter valued at approximately $351,000. Lazard Asset Management LLC raised its position in shares of AxoGen by 30.1% in the first quarter. Lazard Asset Management LLC now owns 11,539 shares of the medical equipment provider’s stock valued at $93,000 after purchasing an additional 2,671 shares during the period. Price T Rowe Associates Inc. MD raised its position in shares of AxoGen by 8.0% in the first quarter. Price T Rowe Associates Inc. MD now owns 29,650 shares of the medical equipment provider’s stock valued at $240,000 after purchasing an additional 2,204 shares during the period. Finally, First Light Asset Management LLC raised its position in shares of AxoGen by 177.0% in the first quarter. First Light Asset Management LLC now owns 765,886 shares of the medical equipment provider’s stock valued at $6,181,000 after purchasing an additional 489,397 shares during the period. Institutional investors own 80.29% of the company’s stock.

AxoGen Trading Down 13.4 %

Shares of AXGN stock opened at $13.27 on Friday. AxoGen, Inc. has a 1 year low of $4.83 and a 1 year high of $15.90. The firm’s fifty day simple moving average is $13.81 and its 200 day simple moving average is $10.07. The firm has a market capitalization of $581.62 million, a P/E ratio of -34.92 and a beta of 1.13. The company has a current ratio of 3.51, a quick ratio of 2.32 and a debt-to-equity ratio of 0.70.

AxoGen (NASDAQ:AXGN) last announced its quarterly earnings results on Thursday, August 8th. The medical equipment provider reported ($0.04) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.14) by $0.10. The firm had revenue of $47.91 million for the quarter, compared to analyst estimates of $43.27 million. AxoGen had a negative net margin of 9.53% and a negative return on equity of 17.30%. As a group, sell-side analysts predict that AxoGen, Inc. will post -0.33 EPS for the current year.

Analyst Upgrades and Downgrades

A number of equities analysts have recently commented on the stock. JMP Securities lifted their price target on shares of AxoGen from $17.00 to $20.00 and gave the company a “market outperform” rating in a research report on Friday, August 9th. StockNews.com raised shares of AxoGen from a “hold” rating to a “buy” rating in a research report on Tuesday, October 15th. Five analysts have rated the stock with a buy rating, According to MarketBeat, AxoGen has a consensus rating of “Buy” and a consensus target price of $15.00.

AxoGen Company Profile

AxoGen, Inc, together with its subsidiaries, develops and commercializes technologies for peripheral nerve regeneration and repair worldwide. The company’s products include Avance Nerve Graft, a biologically active off-the-shelf processed human nerve allograft for bridging severed peripheral nerves without the comorbidities associated with a second surgical site; AxoGuard Nerve Connector, a porcine submucosa extracellular matrix (ECM) coaptation aid for tensionless repair of severed peripheral nerves; AxoGuard Nerve Protector, a porcine submucosa ECM product that is used to wrap and protect damaged peripheral nerves, as well as reinforces the nerve reconstruction while preventing soft tissue attachments; and Axoguard HA+ Nerve Protector, a processed porcine submucosa ECM base layer with a hyaluronate-alginate gel coating designed to provide short- and long-term protection for peripheral nerve injuries.